Bayer AG ((BAYRY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting an observational study titled ‘SMART-Finder – Identification of Patients With Elevated UACR Levels in a T2DM Cohort.’ The study aims to identify patients with type 2 diabetes mellitus (T2DM) who have elevated urine-albumin-creatinine-ratio (UACR) levels, a marker for kidney damage, using the myTherapy app in Germany. This research is significant as it seeks to understand the prevalence and progression of kidney damage in T2DM patients, a critical complication that can lead to chronic kidney disease (CKD).
Intervention/Treatment: The study involves the use of the myTherapy app by T2DM patients to track their condition and treatment. Participants are prescribed drugs for T2DM, including Finerenone (Kerendia, BAY94-8862), based on physician recommendations. The study does not involve any additional interventions beyond routine care.
Study Design: This is an observational cohort study with data collected from participants using the myTherapy app. The study does not involve random allocation or masking, focusing instead on real-world data collection to observe changes in UACR levels over time.
Study Timeline: The study began in October 2022, with data collection expected to continue until December 2024. The primary completion date is set for 15 months after each participant’s start date. The latest update was submitted in August 2025, indicating ongoing data analysis and study progress.
Market Implications: Bayer’s study could positively impact its stock performance by demonstrating commitment to addressing complications of T2DM, a growing global health concern. Successful outcomes might enhance investor confidence and position Bayer favorably against competitors in the diabetes care market, potentially leading to increased market share and investor interest.
The study is ongoing, with further details available on the ClinicalTrials portal.